C-3 substituted oleanolic acid benzamide derivative as well as preparation method and application thereof
By developing C-3-substituted benzylamide derivatives, the problem of limited selection of existing anti-influenza drugs has been solved, and effective inhibition of influenza A virus H1N1 has been achieved, with good application prospects.
Patent Information
- Application Number
- CN202410914274.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-09
AI Technical Summary
The existing anti-influenza virus drug selection is limited, making it difficult to effectively deal with the mutant strain of influenza A virus.
A C-3-substituted benzylamide derivative of oleanolic acid and its preparation method are developed, and the compound is synthesized through acetylation reaction, acid chloride condensation, hydrolysis and other steps, and applied to anti-influenza virus drugs.
This compound has good inhibitory activity on influenza A virus H1N1, has good application prospects for preventing and treating influenza virus infection, and has expanded the application value of oleanolic acid amide derivatives.
Smart Images

Figure CN118994291A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology and more specifically relates to a C-3 substituted oleanolic acid benzylamide derivative and a preparation method and application thereof. Background Art
[0002] The continuous mutation of influenza A virus poses a serious threat to the life and health of people around the world. Every year, hundreds of thousands of people die from serious diseases caused by influenza A virus infection worldwide. It is also the main cause of death among the elderly and people with weakened immune systems. The symptoms of influenza A virus are respiratory symptoms and fever. In severe cases, it can cause pneumonia, and even respiratory failure, multiple organ failure, and death.
[0003] To date, there are three main categories of anti-influenza virus drugs, including M2 proton channel inhibitors (amantadine and rimantadine), neuraminidase (NA) inhibitors (oseltamivir, peramivir, zanamivir and lanamivir) and RNA-dependent RNA polymerase (RdRp) inhibitors. Influenza virus RdRp is a heterotrimeric complex composed of polymerase acidic subunit (PA), polymerase basic subunit 1 (PB1) and polymerase basic subunit 2 (PB2). Recently, two RdRp inhibitors have been launched on the market, namely PA inhibitor baloxavir and PB1 inhibitor fapira, showing good application prospects of RdRp inhibitors as anti-influenza virus drugs, but the available anti-influenza virus drugs are still limited.
[0004] In order to cope with the continuous emergence of influenza A virus variants, my country still needs to accelerate in-depth research on conservative potential drug targets in influenza A virus strains such as H1N1, and strengthen continuous scientific research on the development of broad-spectrum anti-influenza virus drugs, in order to obtain a variety of candidate drug reserves with novel mechanisms of action, so as to better protect people's lives and health. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the defects and shortcomings of the existing available anti-influenza virus drugs on the market, which are still limited, and to provide a C-3 substituted oleanolic acid benzylamide derivative.
[0006] The object of the present invention is to provide a method for preparing the C-3 substituted oleanolic acid benzylamide derivative.
[0007] Another object of the present invention is to provide the application of the C-3 substituted oleanolic acid benzylamide derivative.
[0008] Another object of the present invention is to provide an anti-influenza virus drug.
[0009] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0010] The present invention protects a C-3 substituted oleanolic acid benzylamide derivative, the structure of the C-3 substituted oleanolic acid benzylamide derivative is shown in the following formula I:
[0011]
[0012] In Formula I, R is R 1 (m1) Substituted benzene ring, R 2 (m2) Substituted benzyl or R 3 (m3) Replace C 3~6 Cycloalkenyl, the R 1 It is single-substituted, multi-substituted or unsubstituted, and m1 represents R on the benzene ring. 1 The number of, m1 is any integer from 0 to 5; the R 1 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy, halogen or C 1~6 alkyl;
[0013] The R 2 It is single-substituted, multi-substituted or unsubstituted, and m2 represents R on the benzene ring. 2 The number of, m2 is any integer from 0 to 5; the R 2 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy, halogen or C 1~6 alkyl;
[0014] The R 3 is monosubstituted, polysubstituted or unsubstituted, and m3 represents R 3 The number of, m3 is any integer from 0 to 5; the R 3 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy, halogen or C 1~6 alkyl;
[0015] The n is any integer from 0 to 6.
[0016] Specifically, the R 1 (m1) is a substituent on the benzene ring, and the hydrogen on the benzene ring is replaced by R 1 Single substitution, multiple substitution or unsubstituted, m1 represents R on the benzene ring 1m1 is any integer from 0 to 5; when m1=0, it means that the H on the benzene ring is not replaced; when m1=1, it means that the H on the benzene ring is replaced by R 1 Monosubstituted; when m1=2-5, it means that the H on the benzene ring is replaced by R 1 Multiple substitution, R at different substitution positions 1 Same or different.
[0017] Specifically, the R 2 (m2) is a substituent on the benzene ring in the benzyl group, and the hydrogen on the benzene ring is replaced by R 2 Single substitution, multiple substitution or unsubstituted, m2 represents R on the benzene ring 2 m2 is any integer from 0 to 5; when m2=0, it means that the H on the benzene ring is not replaced; when m2=1, it means that the H on the benzene ring is replaced by R 2 Monosubstituted; when m2 = 2 to 5, it means that the H on the benzene ring is replaced by R 2 Multiple substitution, R at different substitution positions 2 Same or different.
[0018] Specifically, the R 3 (m3) is a substituent on a cycloalkenyl group, the hydrogen on the cycloalkenyl group is replaced by R 3 Single substitution, multiple substitution or unsubstituted, m3 represents R on the cycloalkenyl group 3 m3 is any integer from 0 to 5; when m3=0, it means that the H on the cycloalkenyl group is not replaced; when m3=1, it means that the H on the cycloalkenyl group is replaced by R 3 Monosubstituted; when m3 = 2 to 5, it means that the H on the cycloalkenyl group is replaced by R 3 Multiple substitution, R at different substitution positions 3 Same or different.
[0019] Preferably, said R is R 1 (m1) Substituted benzene ring, R 2 (m2) Substituted benzyl or R 3 (m3) Replace C 5~6 Cycloalkenyl, the R 1 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy or halogen, the R 2 is selected from hydrogen or hydroxyl, said R 3 is selected from hydrogen or hydroxyl; said m1, m2, m3 are each independently selected from any natural number from 0 to 3; said n is 0 or 1.
[0020] More preferably, the R 1 Each independently selected from hydrogen, hydroxyl, C 1~3 Alkoxy or halogen.
[0021] More preferably, the R 1 Each independently selected from hydrogen, hydroxyl, C 1~3 Alkoxy or fluorine.
[0022] More preferably, R is selected from phenol, diphenol, pyrogallol, 1~3 Alkoxy substituted phenyl, difluorophenyl, dihydroxy substituted benzyl or trihydroxy substituted cyclohexenyl.
[0023] More preferably, R is selected from 4-hydroxy substituted phenyl, 3,4-dihydroxy substituted phenyl, 3,4,5-trihydroxy substituted phenyl, 2,3-dihydroxy substituted phenyl, 3,5-dihydroxy substituted phenyl, 2,4-dihydroxy substituted phenyl, 3,4-dimethoxy substituted phenyl, 3,4-difluoro substituted phenyl, 3,4-dihydroxy substituted benzyl or 3,4,5-trihydroxy substituted cyclohexenyl.
[0024] Furthermore, the C-3 substituted oleanolic acid benzylamide derivative also includes pharmaceutically acceptable salts, crystal forms, solvates, stereoisomers or isotope-substituted compounds thereof.
[0025] The present invention provides a method for preparing the C-3 substituted oleanolic acid benzylamide derivative, comprising the following steps:
[0026] S1. Under normal temperature conditions, oleanolic acid is used as a raw material and an acetylation reaction is performed to obtain the intermediate compound 1:
[0027]
[0028] S2. At room temperature, the intermediate compound 1 obtained in step S1 is reacted with oxalyl chloride to generate an acyl chloride intermediate, triethylamine is added as an acid binding agent, and then condensed with benzylamine to generate an intermediate compound 2:
[0029]
[0030] S3. At 45-50° C., the intermediate compound 2 obtained in step S2 is hydrolyzed under the action of an alkaline reagent to obtain an intermediate compound 3:
[0031]
[0032] S4. Under ice bath conditions, the intermediate compound 3 obtained in step S3 and compound P-1 are mixed evenly, and a condensation reaction is carried out under an inert protective atmosphere at room temperature to obtain an intermediate compound 4:
[0033]
[0034] S5. At room temperature, the intermediate compound 4 obtained in step S4 is selectively deprotected by TBDMS to obtain the intermediate compound 5:
[0035]
[0036] S6. Under ice bath conditions, the intermediate compound 5 obtained in step S5 and compound P-2 are uniformly mixed, and a condensation reaction is carried out under an inert protective atmosphere at room temperature to obtain an intermediate compound 6-n:
[0037]
[0038] S7. Under normal temperature and inert protective atmosphere, the intermediate compound 6-n obtained in step S6 is selectively deprotected by the Boc (tert-butyloxycarbonyl) protecting group to obtain an intermediate compound of the general formula 7-n:
[0039]
[0040] S8. Under ice bath conditions, the intermediate compound obtained in step S7 is mixed evenly with compound P-3, and a condensation reaction is carried out under an inert protective atmosphere and room temperature conditions to obtain an intermediate compound of the general formula 8-n:
[0041]
[0042] Wherein, the definition of R' is: when R in formula (I) is R 1 (m1) Substituted benzene ring or R 2 (m2) substituted benzyl, and R 1 , R 2 is a hydroxyl group, then R' is the group after the hydrogen of the hydroxyl group in R is replaced by Bn; when the R is selected from R 3 (m3) Replace C 3~6 Cycloalkenyl, and R 3 is a hydroxyl group, then R' is the group after the hydrogen of the hydroxyl group in R is replaced by TBDMS: In other cases, R' has the same definition as R;
[0043] S9. When R 'does not contain TBDMS: Under normal temperature conditions and a hydrogen atmosphere, the intermediate compound 8-n obtained in step S8 is deprotected from the benzyl protecting group to obtain the C-3 substituted oleanolic acid benzylamide derivative;
[0044] When R' contains TBDMS: at room temperature, the intermediate compound 8-n obtained in step S8 is first selectively deprotected from the TBDMS protecting group, and then the benzyl protecting group is deprotected at -75 to -80°C in an inert protective atmosphere to obtain the substituted oleanolic acid benzylamide derivative with C-3:
[0045]
[0046] Wherein, the definitions of n and R are the same as those described above.
[0047] Furthermore, in step S1, the oleanolic acid is subjected to an acetylation reaction under the action of an acetylation agent and a catalyst.
[0048] Preferably, the acetylating agent is acetic anhydride or acetyl chloride, and the catalyst is preferably 4-dimethylaminopyridine.
[0049] Furthermore, the molar ratio of oleanolic acid, acetylation agent and catalyst is 1:(1.5-2):(0.1-0.2).
[0050] Furthermore, the reaction solvent used in the acetylation reaction is pyridine, dichloromethane or a combination thereof.
[0051] Furthermore, in step S2, the reaction solvent used in the condensation reaction is preferably dichloromethane, tetrahydrofuran or N,N-dimethylformamide.
[0052] Furthermore, the molar ratio of the intermediate compound 1, oxalyl chloride, triethylamine and benzylamine is 1:(3-5):(3-5):(1.5-2.5).
[0053] Furthermore, in step S3, the alkaline reagent is selected from sodium hydroxide, potassium hydroxide or lithium hydroxide, preferably sodium hydroxide.
[0054] Furthermore, in step S3, a catalyst needs to be added, and the catalyst is a quaternary ammonium salt compound, preferably tetrabutylammonium iodide, benzyltriethylammonium chloride, tetrabutylammonium bromide or tetrabutylammonium chloride, more preferably tetrabutylammonium iodide.
[0055] Furthermore, the molar ratio of the intermediate compound 2 to the catalyst is 1:(0.4-0.6).
[0056] Furthermore, in step S3, the reaction solvent used in the hydrolysis reaction is tetrahydrofuran, methanol or a combination thereof.
[0057] Furthermore, in step S4, the condensation reaction is carried out under the action of a condensation agent and a catalyst, the condensation agent is preferably 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and the acylation catalyst is preferably 4-dimethylaminopyridine.
[0058] Preferably, the molar ratio of the condensing agent to the acylation catalyst is 1:(0.05-0.25).
[0059] Furthermore, in step S4, the reaction solvent used in the condensation reaction is preferably dichloromethane, tetrahydrofuran or N,N-dimethylformamide.
[0060] Preferably, in step S4, the molar ratio of the intermediate compound 3, compound P-1 and the condensing agent is 1:(1.45-1.55):(2.25-2.75).
[0061] Furthermore, in step S5, the reaction of selectively removing the TBDMS (tert-butyldimethylsilyl) protecting group is carried out under the action of a catalyst, and the catalyst is tetrabutylammonium fluoride or its hydrate or acetic acid.
[0062] Furthermore, in step S5, the reaction solvent used in the reaction of selectively removing the TBDMS protecting group is preferably tetrahydrofuran, dichloromethane or N,N-dimethylformamide.
[0063] Preferably, the molar ratio of the intermediate compound 4 to the catalyst is 1:(4-6).
[0064] Furthermore, in step S6, the condensation reaction is carried out under the action of a condensation agent and an acylation catalyst, the condensation agent is preferably 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and the acylation catalyst is preferably 4-dimethylaminopyridine.
[0065] Preferably, the molar ratio of the condensing agent to the acylation catalyst is 1:(0.05-0.25).
[0066] Furthermore, the molar ratio of the intermediate compound 5, compound P-2 and the condensing agent is 1:(1.8-2.2):(2.4-2.8).
[0067] Furthermore, in step S6, the reaction solvent used in the condensation reaction is dichloromethane, tetrahydrofuran or N,N-dimethylformamide.
[0068] Furthermore, in step S7, the reaction of selectively removing the Boc protecting group is carried out under the action of a catalyst, and the catalyst is trifluoroacetic acid.
[0069] Furthermore, in step S7, the reaction solvent used in the selective removal of the Boc protecting group is dichloromethane, tetrahydrofuran or N,N-dimethylformamide.
[0070] Furthermore, the molar ratio of the intermediate compound 6-n to the catalyst is 1:(8-22).
[0071] Further, in step S8, the condensation reaction is carried out under the action of a condensation agent, an acylation catalyst, and an organic base, wherein the condensation agent is preferably 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), the acylation catalyst is preferably 1-hydroxy-7-azidobenzotriazole (HOAt) (mainly used to inhibit the racemization reaction), and the organic base is preferably N-methylmorpholine (NMM) (to deprotonate the carboxylic acid).
[0072] Preferably, the molar ratio of the condensing agent, the acylation catalyst and the organic base is 1:1:(1.1-1.5).
[0073] Furthermore, in step S8, the molar ratio of the intermediate compound 7-n, compound P-3 and the condensing agent is 1:(1.8-2.2):(2.2-2.8).
[0074] Furthermore, in step S8, the reaction solvent used in the condensation reaction is dichloromethane, tetrahydrofuran or N,N-dimethylformamide.
[0075] Furthermore, in step S9, when R' does not contain TBDMS, the reaction of removing the benzyl (Bn) protecting group on the hydroxyl group is carried out under the action of a catalyst Pd / C (palladium on carbon).
[0076] Furthermore, when R' does not contain TBDMS, the mass ratio of the intermediate compound 8-n to Pd / C is 1:(0.1-0.2).
[0077] Furthermore, in step S9, the reaction solvent for removing the benzyl protecting group on the hydroxyl group is preferably tetrahydrofuran, methanol or a combination thereof.
[0078] Furthermore, in step S9, when R' contains TBDMS, the reaction of selectively removing the TBDMS (tert-butyldimethylsilyl) protecting group is carried out under the action of a catalyst, and the catalyst is tetrabutylammonium fluoride or its hydrate or acetic acid.
[0079] Preferably, when R' contains TBDMS, the molar ratio of the intermediate compound 8-n to the catalyst is 1:(4-6).
[0080] Furthermore, the reaction solvent used in the reaction of selectively removing the TBDMS protecting group is preferably tetrahydrofuran, dichloromethane or N,N-dimethylformamide.
[0081] Furthermore, in step S9, when R' contains TBDMS, the reaction of selectively removing the Bn (benzyl) protecting group is carried out under the action of a catalyst, and the catalyst is preferably boron trichloride.
[0082] Furthermore, in step S9, when R' contains TBDMS, in the reaction of selectively removing the Bn (benzyl) protecting group, the molar ratio of compound 8-n to the catalyst is 1:(2.2-2.8).
[0083] Furthermore, the gas of the inert protective atmosphere is selected from nitrogen, neon, argon or helium.
[0084] Furthermore, the reaction in step S1 also includes post-treatment to obtain the intermediate compound 1, and the post-treatment includes reduced pressure evaporation, washing, drying and silica gel column chromatography.
[0085] Specifically, the post-treatment is to evaporate the solvent under reduced pressure, dissolve the residue in DCM (dichloromethane), wash with 1M hydrochloric acid, saturated NaHCO3 solution, and saturated NaCl solution for multiple times (preferably 3 times), dry with anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 6 / 1 / 1) to obtain the intermediate compound 1.
[0086] Furthermore, the reaction in step S2 also includes post-treatment to obtain the intermediate compound 2, and the post-treatment includes reduced pressure evaporation, washing, drying and silica gel column chromatography.
[0087] Specifically, the post-treatment is to evaporate the solvent under reduced pressure, dissolve the residue in DCM, wash with water and saturated NaCl solution for multiple times (preferably 3 times), dry with anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 4 / 1 / 1) to obtain the intermediate compound 2.
[0088] Furthermore, the reaction in step S3 also includes post-treatment to obtain the intermediate compound 3, and the post-treatment includes reduced pressure evaporation, washing, drying and silica gel column chromatography.
[0089] Specifically, the post-treatment is to concentrate under reduced pressure to remove most of the solvent, dissolve the residue in DCM, wash with water and saturated NaCl solution for multiple times (preferably 3 times), dry with anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 2 / 1 / 1) to obtain the intermediate compound 3.
[0090] Furthermore, the reaction in step S4 also includes post-treatment to obtain the intermediate compound 4, and the post-treatment includes dilution, washing, drying and silica gel column chromatography.
[0091] Specifically, the post-treatment is to dilute the reaction mixture with dichloromethane, wash it with 1M hydrochloric acid saturated NaCl solution for multiple times (preferably 3 times), dry it with anhydrous Na2SO4, and chromatograph it on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 8 / 1 / 1) to obtain the intermediate compound 4.
[0092] Furthermore, the reaction in step S5 also includes post-treatment to obtain an intermediate compound 5, and the post-treatment includes evaporation under reduced pressure, washing, drying and silica gel column chromatography.
[0093] Specifically, the post-treatment is to concentrate under reduced pressure to remove most of the solvent, dissolve the residue in ethyl acetate, wash with 1M hydrochloric acid saturated NaCl solution for multiple times, dry over anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 2 / 1 / 1) to obtain the intermediate compound 5.
[0094] Furthermore, the reaction in step S6 also includes post-treatment to obtain intermediate compounds 6-n, 7-n, and the post-treatment includes dilution, washing, drying and silica gel column chromatography.
[0095] Specifically, the post-treatment is to dilute the reaction mixture with dichloromethane, wash it with 1M hydrochloric acid saturated NaCl solution for multiple times (preferably 3 times), dry it with anhydrous Na2SO4, and chromatograph it on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 6 / 1 / 1) to obtain the intermediate compound 6.
[0096] Furthermore, the reaction in step S7 also includes post-treatment to obtain the intermediate compound 7-n, and the post-treatment includes terminating the reaction, washing, and drying.
[0097] Specifically, the post-treatment is to add saturated sodium bicarbonate solution under ice bath to terminate the reaction, dilute the obtained mixture with dichloromethane, wash with water and NaCl solution for multiple times (preferably 3 times), and dry with anhydrous Na2SO4 to obtain the intermediate compound 7-n.
[0098] Furthermore, the reaction in step S8 also includes post-treatment to obtain the intermediate compound 8-n, and the post-treatment includes dilution, washing, drying and silica gel column chromatography.
[0099] Specifically, the post-treatment is to dilute the reaction mixture with dichloromethane, wash it three times with 1M hydrochloric acid saturated NaCl solution, dry it with anhydrous Na2SO4, and chromatograph it on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 3 / 1 / 1) to obtain the intermediate compound 8-n.
[0100] Furthermore, the reaction in step S9 also includes post-treatment, and the target compound C-3 obtained by post-treatment is a substituted oleanolic acid benzylamide derivative, and the post-treatment includes filtration, reduced pressure evaporation, and silica gel column chromatography.
[0101] Specifically, the post-treatment is filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography (V dichloromethane / V methanol / V formic acid = 100 / 10 / 1) to obtain the target compound.
[0102] The present invention protects the use of the C-3 substituted oleanolic acid benzylamide derivative in the preparation of anti-influenza virus drugs.
[0103] Preferably, the influenza virus is influenza A virus.
[0104] The present invention also protects an anti-influenza virus drug comprising one or more of the C-3 substituted oleanolic acid benzylamide derivatives.
[0105] Compared with the prior art, the present invention has the following beneficial effects: the C-3 substituted oleanolic acid benzylamide derivatives of the present invention have a novel chemical structure, and have good inhibitory activity against influenza viruses, especially influenza A virus H1N1, both in vivo and in vitro, indicating that the compounds can be prepared into anti-influenza virus preparations, and have good application prospects in preventing and / or treating influenza virus infections, thereby expanding the application value of C-3 substituted oleanolic acid amide derivatives. BRIEF DESCRIPTION OF THE DRAWINGS
[0106] Figure 1 The figure is a statistical graph showing the effect of intraperitoneal injection of various doses of compound I-1 on the body weight changes of mice after they were infected with influenza A virus.
[0107] Figure 2 The figure is a statistical graph showing the effect of intraperitoneal injection of various doses of compound I-1 on the survival rate of mice after they were infected with influenza A virus.
[0108] Figure 3 The statistical graph shows the effect of intraperitoneal injection of various doses of compound I-1 on the changes in lung index of mice after they were infected with influenza A virus. Compared with the data of the Model group, * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, **** indicates p<0.0001, and ns indicates no significant difference.
[0109] Figure 4 This is a statistical graph showing the effect of intraperitoneal injection of various doses of compound I-1 on the viral protein content in the lung tissue of mice infected with influenza A virus.
[0110] Figure 5 Compound I-1 reacts with PA within a certain concentration range (239-716aa) Statistical graph of protein binding data.
[0111] Figure 6 Compound I-1 at different concentrations and PA C-PB1 N Statistical diagram of the relationship between protein binding and inhibition rate. DETAILED DESCRIPTION
[0112] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0113] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0114] Example 1 Preparation of Compound Ⅰ-1
[0115] The preparation of compound Ⅰ-1, the synthetic route is shown below:
[0116]
[0117] a. Ac2O (acetic anhydride), DMAP (4-dimethylaminopyridine), Pyridine (pyridine); b. (1) (COCl)2 (oxalyl chloride, also known as oxalyl chloride), DCM (dichloromethane); (2) TEA (triethylamine), BnNH2 (benzylamine), DCM; c. TBAI (tetrabutylammonium iodide), NaOH, THF-MeOH (tetrahydrofuran-methanol solution); d. EDC·HCl (1-ethyl-(3-dimethylammonium) e. TBAF·3H2O (tetrabutylammonium fluoride trihydrate), THF; f. EDC·HCl, DMAP, DCM; g. CF3COOH, DCM; h. EDC·HCl, HOAT (1-hydroxy-7-azobenzotriazole), NMM (N-methylmorpholine), DCM; i. Pd / C (palladium on carbon), H2, MeOH-THF (methanol-tetrahydrofuran solution).
[0118] (1) Preparation of intermediate compound 1
[0119] Oleanolic acid (10 g, 21.90 mmol) was dissolved in 80 mL of pyridine, and DMAP (0.27 g, 2.19 mmol) and acetic anhydride (3.14 mL, 32.87 mmol) were added at 0°C, stirred for 30 min, and then transferred to room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was dissolved in DCM, washed with 1 M hydrochloric acid, saturated NaHCO3 solution, and saturated NaCl solution three times in sequence, dried over anhydrous Na2SO4, and chromatographed on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 6 / 1 / 1) to obtain a white solid product, namely, intermediate compound 1 (9.51 g, yield 87.06%).
[0120] (2) Preparation of intermediate compound 2
[0121] Take the intermediate compound 1 (4g, 8.02mmol) and dissolve it in 40mL dry dichloromethane, add oxalyl chloride (2.71mL, 32.08mmol), stir at room temperature for 24h, evaporate the solvent under reduced pressure, repeat three times, dissolve the residue in 30mL DCM and evaporate the solvent under reduced pressure, dissolve the acyl chloride intermediate in 40mL DCM, add triethylamine (4.43mL, 32.08mmol) and benzylamine (1.75mL, 16.04mmol) under ice bath and stir for 30min, transfer to room temperature and stir overnight. Evaporate the solvent under reduced pressure, dissolve the residue in DCM, wash with water and saturated NaCl solution three times in sequence, dry over anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 4 / 1 / 1) to obtain a white solid product, namely, the intermediate compound 2 (4.37g, yield 92.75%).
[0122] (3) Preparation of intermediate compound 3
[0123] Take the intermediate compound 2 (4.37 g, 7.44 mmol) and dissolve it in 50 mL (V tetrahydrofuran / V methanol = 3 / 2) mixed solvent, add TBAI (1.37 g, 3.72 mmol), slowly add 4N sodium hydroxide solution dropwise to adjust the system to alkalinity, and reflux at 50°C overnight. Add 1M hydrochloric acid to adjust the pH of the system to 7, concentrate under reduced pressure to remove most of the solvent, and dissolve the residue in DCM, wash with water and saturated NaCl solution three times in sequence, dry over anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 2 / 1 / 1) to obtain a white solid product, intermediate compound 3 (3.65 g, yield 89.94%).
[0124] (4) Preparation of intermediate compound 4
[0125] (2R, 4S)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-2-carboxylic acid (1.42 g, 4.13 mmol) was dissolved in 30 mL of dry dichloromethane, and 4-dimethylaminopyridine (67 mg, 0.55 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.32 g, 6.88 mmol) and intermediate compound 3 (1.5 g, 2.75 mmol) were added in sequence at -20°C (i.e., under ice bath conditions), and stirred for 30 min. The mixture was reacted at room temperature overnight under N2 protection. The mixture was diluted with dichloromethane, washed three times with 1M hydrochloric acid saturated NaCl solution, dried over anhydrous Na2SO4, and chromatographed on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 8 / 1 / 1) to obtain a white solid product, intermediate compound 4 (2.11 g, yield 87.92%).
[0126] (5) Preparation of intermediate compound 5
[0127] Take the intermediate compound 4 (1.8 g, 2.06 mmol) and dissolve it in 30 mL of tetrahydrofuran, add tetrabutylammonium fluoride trihydrate (3.31 g, 10.31 mmol) at 0°C, stir for 15 min, and transfer to room temperature to react overnight. Concentrate under reduced pressure to remove most of the solvent, dissolve the residue in ethyl acetate, wash with 1M hydrochloric acid saturated NaCl solution three times, dry with anhydrous Na2SO4, and chromatograph on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 2 / 1 / 1) to obtain a white solid product, namely the intermediate compound 5 (1.31 g, yield 84.47%).
[0128] (6) Preparation of intermediate compound 6
[0129] 3,4-dibenzylbenzoic acid (0.87 g, 2.62 mmol) was dissolved in 20 mL of dry dichloromethane, and 4-dimethylaminopyridine (31 mg, 0.26 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.63 g, 3.25 mmol) and intermediate compound 5 (1 g, 1.31 mmol) were added in sequence at -20°C (i.e., under ice bath conditions), and stirred for 30 min. The mixture was reacted at room temperature overnight under N2 protection. The mixture was diluted with dichloromethane, washed three times with 1M hydrochloric acid saturated NaCl solution, dried over anhydrous Na2SO4, and chromatographed on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 6 / 1 / 1) to obtain a white solid product, namely intermediate compound 6 (734 mg, yield 53.18%).
[0130] (7) Preparation of intermediate compound 7
[0131] Intermediate compound 6 (400 mg, 0.38 mmol) was dissolved in 2.5 mL of dry dichloromethane, trifluoroacetic acid (0.62 mL, 7.6 mmol) was added, and the mixture was stirred at room temperature for 2 h under N2 protection. Saturated sodium bicarbonate solution was added under ice bath to terminate the reaction, and the mixture was diluted with dichloromethane, washed with water and NaCl solution three times in sequence, and dried over anhydrous Na2SO4 to obtain a white solid product, namely intermediate compound 7 (360 mg, yield 97.21%).
[0132] (8) Preparation of intermediate compound 8
[0133] 3,4-dibenzylbenzoic acid (127 mg, 0.76 mmol) was dissolved in 20 mL of dry dichloromethane, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (182 mg, 0.95 mmol), 1-hydroxy-7-azidobenzotriazole (129 mg, 0.95 mmol), intermediate compound 7 (370 mg, 0.38 mmol) and N-methylmorpholine (128 μL, 1.14 mmol) were added in sequence at -20°C (i.e., under ice bath conditions), and then stirred for 10 min. The mixture was reacted at room temperature overnight under N2 protection. The mixture was diluted with dichloromethane, washed three times with 1M hydrochloric acid saturated NaCl solution, dried over anhydrous Na2SO4, and chromatographed on a silica gel column (V petroleum ether / V ethyl acetate / V dichloromethane = 3 / 1 / 1) to obtain a white solid product, namely intermediate compound 8 (200 mg, yield 40.77%).
[0134] (9) Preparation of Compound I-1
[0135] The intermediate compound 8 (200 mg, 0.15 mmol) was dissolved in 6 mL (V tetrahydrofuran / V methanol = 1 / 1) mixed solvent, Pd / C (20 mg) was added, and the mixture was reacted at room temperature in a H2 environment for 24 h. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the mixture was chromatographed on a silica gel column (V dichloromethane / V methanol / V formic acid = 100 / 10 / 1) to obtain a gray solid product, namely compound Ⅰ-1 (80 mg, yield 57.31%).
[0136] Example 2 Preparation of Compounds I-2 to I-9
[0137] According to the preparation process of compound I-1 obtained in Example 1 above, the R substituent and the number of carbon chain atoms n in the compound represented by formula I are replaced as shown in Table 1 to obtain the corresponding product represented by formula 1. It should be noted that when preparing compound I-2, the specific preparation example of step (9) is as follows:
[0138]
[0139] Take the intermediate compound 8-2 (500 mg, 0.33 mmol) and dissolve it in 10 mL of tetrahydrofuran. Add tetrabutylammonium fluoride trihydrate (535 mg, 1.69 mmol) at 0 ° C and stir for 15 min. Transfer to room temperature and react overnight. Concentrate under reduced pressure to remove most of the solvent, dissolve the residue in ethyl acetate, wash with 1M hydrochloric acid saturated NaCl solution three times in sequence, and dry over anhydrous Na2SO4 to obtain a mixture of yellow solids. Dissolve the mixture in 10 mL of dry dichloromethane, slowly add about 0.85 ml of 1M boron trichloride dichloromethane solution at -78 ° C, stir at -78 ° C for half an hour under N2 protection, add saturated aqueous ammonium chloride to quench the reaction, concentrate under reduced pressure, and chromatograph on a silica gel column (V dichloromethane / V methanol / V formic acid = 100 / 10 / 1) to obtain a purple solid Ⅰ-2 (110 mg, yield 35.06%).
[0140] The other steps are basically the same as those in the preparation of compound I-1 obtained in Example 1.
[0141] The results of H NMR spectrum detection of the above obtained compounds are shown in Table 1 below.
[0142] Table 1 Appearance and H NMR spectrum data of target compounds
[0143]
[0144]
[0145]
[0146]
[0147] Example 2 Evaluation of the cytotoxic effects of the compounds obtained in Example 1 and Example 2 on MDCK cells (CC 50 ) and its anti-influenza A virus (A / WSN / 33 / H1N1) activity on cells (EC 50 )
[0148] The C-3 substituted oleanolic acid benzylamide derivatives prepared in Example 1 and Example 2 were used as test objects to test their inhibitory activity against the H1N1 influenza A virus strain (A / WSN / 33 / H1N1) on MDCK cells.
[0149] 1. Experimental methods
[0150] MDCK cells were inoculated in a 96-well cell plate, and washed twice with sterile PBS after the cell density reached more than 90%. The compound was diluted 2-fold with DMEM basic maintenance solution without FBS, and nine different compound concentration groups of 0.39, 0.78, 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 μM were set up, and a 0.1% DMSO solvent control group was set up. Each group was set up with 3 replicate wells, and each well was 200 μL. The plate was placed in a 37°C, 5% CO2 constant temperature incubator for culture. After 48 hours, the culture was terminated, the supernatant was discarded, and CCK8 solution diluted with DMEM basic maintenance solution was added to each well, and incubated in a 37°C, 5% CO2 constant temperature incubator in the dark. After 1 hour, the OD value was measured at 450 nm using a multifunctional microplate reader to calculate the cell survival rate, and the 50% cytotoxic concentration (CC) of compound I-1 on MDCK cells was calculated using GraphPad Prism 9.0 software. 50 ).
[0151] The calculation formula is as follows:
[0152]
[0153] As above, after the MDCK cells grew to a monolayer, they were washed twice with PBS, and the A / WSN / 33 / H1N1 virus was diluted to 100 TCID in DMEM basal maintenance medium without FBS. 50 The virus solution was used to set up a cell blank control group, which was placed in a 37°C, 5% CO2 constant temperature incubator for 1 hour, and the supernatant was discarded. The compound was diluted twice with a DMEM basic maintenance solution containing 0.5μg / mL TPCK-trypsin, and a solvent control group, a virus control group, a zanamivir positive control group, and a compound drug group with a concentration gradient of 0.31-20μM were set up, with 200μL per well. The cells were cultured in a 37°C, 5% CO2 constant temperature incubator for 36-48h, the pathological changes of the virus control group were observed, the maintenance supernatant was discarded, and CCK8 solution diluted with DMEM basic maintenance solution was added to each well, and the cells were incubated in a 37°C, 5% CO2 constant temperature incubator in the dark. After 1 hour, the OD value was detected at a wavelength of 450nm using a multifunctional microplate reader, and the inhibition rate of the drug treatment group on the virus at each concentration was calculated to determine the half effective concentration (EC 50 ) values and calculated by nonlinear regression function using GraphPad Prism 9.0 software.
[0154] The calculation formula is as follows:
[0155]
[0156] 2. Experimental results
[0157] The measured results are shown in Table 2.
[0158] Table 2C-3 Inhibitory activity of substituted oleanolic acid benzylamide derivatives against influenza A virus H1N1 (A / WSN / 33) on MDCK cells
[0159] Compound <![CDATA[EC 50 (μM)]]> <![CDATA[CC 50 (μM)]]> OA() 79.2±1.86 >100 I-1 0.76±0.12 111.01±12.11 I-2 10.53±1.26 78.31±9.21 I-3 1.36±0.27 93.95±7.41 I-4 2.13±0.58 90.77±7.11 I-5 4.57±0.39 103.63±10.39 I-6 2.63±0.81 99.31±8.44 I-7 18.21±0.65 76.59±6.97 I-8 25.82±2.03 123.63±10.21 I-9 35.60±1.91 109.21±9.67
[0160] As can be seen from Table 2, the compounds of Formula I all have certain inhibitory activity against influenza A virus H1N1 in MDCK cells, which is stronger than oleanolic acid (OA, EC 50 =79 μM). Among them, the inhibitory EC of compound I-1 on influenza A virus H1N1 was 50 Less than 1 μM, and less toxic to MDCK cells (CC 50 =111 μM), which is much lower than the concentration used, and has broad application value in the preparation of anti-influenza A virus preparations. Therefore, compound I-1 was used as a representative compound for subsequent experiments.
[0161] Example 4 Evaluation of the in vivo anti-influenza A virus (A / WSN / 33 / H1N1) activity of compound I-1
[0162] 1. Experimental methods
[0163] 48 SPF BALB / c mice (half male and half female) were randomly divided into 6 groups, 8 in each group. They were solvent control group (Control), virus group (Model), positive drug oseltamivir phosphate (Oseltamivir phosphate, referred to as Oseltamivir or OSP) group, and compound I-1 treatment groups with three dose gradients of 12.5, 25, and 50 mg / kg. After one week of adaptive breeding in the laboratory, the mice were anesthetized by inhalation of isoflurane. Except for the solvent control group, each mouse was intranasally inoculated with 50 μL of a titer of 5×LD 50 The mice were injected with influenza A virus (A / WSN / 33 / H1N1) and injected intraperitoneally 6 hours later with solvent, 10 mg / kg oseltamivir phosphate solution or 12.5, 25, 50 mg / kg compound I-1. The solvent was 8% DMSO + 32% PEG300 + 5% Tween-80 + 55% saline. The mice were sterilized by filtration with a 0.22 μm filter membrane and the administration was continued for five days. The weight and death of the mice were recorded daily. When the weight loss of the mice was observed to be 20% of the original weight, euthanasia was performed in accordance with animal ethical standards.
[0164] As above, 36 SPF BALB / c mice (half male and half female) were randomly divided into 6 groups, 6 in each group. They were solvent control group, virus group, positive drug oseltamivir group, and three dose gradients of compound I-1 at 12.5, 25, and 50 mg / kg. After one week of adaptive breeding in the laboratory, the mice were anesthetized by inhalation of isoflurane. Except for the solvent control group, each mouse was intranasally inoculated with 50 μL of 1000 TCID 50 The mice were inoculated with influenza A virus (A / WSN / 33 / H1N1), and 6 hours later, the solvent, 10 mg / kg oseltamivir phosphate solution or 12.5, 25, 50 mg / kg compound I-1 were intraperitoneally injected for three consecutive days. The weight of the mice was recorded, and the lungs were sampled to record the weight of the complete lung tissue. The ratio of lung weight (mg) to body weight (g) was the lung index; protein lysis buffer was added to the lung tissue, and the protein was extracted from the tissue homogenate and then Western blotting was performed. Viral protein antibodies PA, PB1, PB2, and NP were used to detect the expression of viral proteins in the lung tissues of each group.
[0165] 2. Experimental results
[0166] The experimental results are as follows Figures 1 to 4 As shown, Figure 1 The results show the effect of intraperitoneal injection of various doses of compound I-1 on the weight change of mice after they were infected with influenza A virus. The weight of mice in the administration groups of various doses decreased more slowly than that in the virus group, and the weight of the administration groups began to rise on the eighth day after infection, indicating that the compound effectively protected the body signs of infected mice; Figure 2 The results show that after mice were infected with influenza A virus, intraperitoneal injection of various doses of compound I-1 had an effect on the survival rate of mice. All mice in the virus group died on the tenth day after infection, while the survival rate of mice in the high-dose I-1 group reached 87.5%. Compound I-1 protected mice from death caused by virus infection in a dose-dependent manner. Figure 3 The results show that after mice were infected with influenza A virus, intraperitoneal injection of various doses of compound I-1 had an effect on the changes in the lung index of mice. The compound I-1-treated group reduced the increase in lung index caused by virus infection in a dose-dependent manner and alleviated the symptoms of pulmonary edema. Figure 4 The effect of intraperitoneal injection of various doses of compound I-1 on the content of viral protein in the lung tissue of mice after they were infected with influenza A virus was shown. The 12.5, 25, and 50 mg / kg dose groups all reduced the expression of viral protein and inhibited the replication of influenza A virus in the lungs of mice. The compound I-1 of the present invention has antiviral activity against A / WSN / 33 / H1N1 virus in mice. The weight loss of mice infected with influenza A virus was alleviated to varying degrees at doses of 12.5, 25, and 50 mg / kg, and some mice were saved from death due to viral infection. The lung index was reduced in a dose-dependent manner, pulmonary edema was alleviated, and the viral load in the lungs was reduced.
[0167] In summary, derivative I-1 has a good protective effect on mice infected with H1N1 influenza virus, can be prepared into an anti-influenza A virus drug for use, and has good application prospects in the prevention and / or treatment of influenza virus infection.
[0168] Example 5 Surface Plasmon Resonance (SPR) Detection of the Interaction between Compound I-1 and the PA-C-terminal (239-716aa) Protein Binding Domain
[0169] 1. Experimental methods
[0170] The purified PA-C-terminal (239-716aa) protein was diluted with PBS to 1 mg / mL and fixed on the surface of the 3D photo-crosslinking chip. After drying, crosslinking, activation, and nitrogen blowing, the chip was tightly fitted to the lid and stored at 4°C for use. Compound I-1 was diluted twice to 0.65-10 μM with a total of five concentration gradients as the mobile phase. The PlexArray HT I-10 instrument was used for analysis. The buffer solution was PBS solution, and the regeneration solution was 10 mM glycine solution with pH = 2.0. The BIAevolution software was used to fit the data and calculate the dissociation constant K D .
[0171] 2. Experimental results
[0172] The experimental results are as follows Figure 5 As shown, the ordinate represents the protein content bound to the compound, and the abscissa represents the protein content bound to the compound. (239-716aa) Compared with the PBS group, compound I-1 had a strong affinity with PA in the concentration range of 650-10000 nM. (239-716aa) The protein has a concentration-dependent binding effect, and the dissociation constant K is calculated. D =9.97×10 -9 M. Dissociation constant K D It is a reaction equilibrium constant used to measure the tendency of a larger object to reversibly separate (dissociate) into smaller components. It is a parameter that describes the strength of intermolecular interactions. In molecular biology, K D Value less than 10 -8 M indicates strong intermolecular binding. The dissociation constant between compound I-1 of the present invention and PA (239-716aa) protein is 9.97×10 -9 M, indicating that the two have high affinity and can effectively bind to the target, inhibiting the replication and transcription process of influenza virus, thus playing an anti-influenza role.
[0173] Example 6 ELISA detection of compound I-1 inhibiting PA C -PB1 Ninteraction
[0174] 1. Experimental methods
[0175] Add 400 ng of purified PA to each well of a 96-well plate. (239-716) Protein was incubated at 4°C overnight and blocked with 2% BSA for 1 h. After rinsing 4 times with PBS-T, a 0.16-10 μM concentration gradient of compound I-1 solution was diluted twice with DMEM basal medium and mixed with 200 ng of purified GST-PB1 (1-25) Protein was added to each well, and GST-PB1 was not added. (1-25) Protein solvent control group and GST-PB1 added (1-25) The 96-well plate was placed at 37°C for 3 h, rinsed 4 times with PBS-T, and then monoclonal GST antibody and its corresponding secondary antibody were added in sequence. After the last wash, TMB kit was used for color development. After 1M sulfuric acid solution was terminated, the OD value was detected at 450nm using a multifunctional microplate reader to calculate the effect of drug treatment groups on PA at each concentration. C -PB1 N The half effective concentration (IC 50 ) values and calculated using GraphPadPrism 9.0 software by nonlinear regression function.
[0176] The calculation formula is as follows:
[0177]
[0178] 2. Experimental results
[0179] The experimental results are as follows Figure 6 As shown, different concentrations of compound I-1 and PA C -PB1 N The relationship between the inhibition rate of protein binding and the inhibitory rate of protein binding. C -PB1 N Protein binding has inhibitory activity, and its IC 50 The value was 0.96 μM, which indicated that compound I-1 inhibited PA C -PB1 N The binding of proteins can prevent the assembly of RNA polymerase and thus inhibit the viral replication process.
[0180] In summary, the C-3 substituted pentacyclic triterpene amide derivatives provided by the present invention have obvious inhibitory effects on influenza A virus H1N1 (A / WSN / 33) in vivo and in vitro, can be prepared into anti-influenza A virus drugs for application, and have good application prospects in the prevention and treatment of influenza virus infection.
[0181] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A C-3 substituted oleanolic acid benzylamide derivative, It is characterized in that The structure of the C-3 substituted oleanolic acid benzylamide derivative is shown in the following formula I: In Formula I, R is R 1 (m1) Substituted benzene ring, R 2 (m2) Substituted benzyl or R 3 (m3) Replace C 3~6 Cycloalkenyl, the R 1 It is single-substituted, multi-substituted or unsubstituted, and m1 represents R on the benzene ring. 1 The number of, m1 is any integer from 0 to 5; the R 1 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy, halogen or C 1~6 alkyl; The R 2 It is single-substituted, multi-substituted or unsubstituted, and m2 represents R on the benzene ring. 2 The number of, m2 is any integer from 0 to 5; the R 2 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy, halogen or C 1~6 alkyl; The R 3 is monosubstituted, polysubstituted or unsubstituted, and m3 represents R 3 The number of, m3 is any integer from 0 to 5; the R 3 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy, halogen or C 1~6 alkyl; The n is any integer from 0 to 6.
2. The C-3 substituted oleanolic acid benzylamide derivative according to claim 1, It is characterized in that The R is R 1 (m1) Substituted benzene ring, R 2 (m2) Substituted benzyl or R 3 (m3) Replace C 5~6 Cycloalkenyl, the R 1 Each independently selected from hydrogen, hydroxyl, C 1~6 Alkoxy or halogen, the R 2 is selected from hydrogen or hydroxyl, said R 3 is selected from hydrogen or hydroxyl; said m1, m2, m3 are each independently selected from any natural number from 0 to 3; said n is 0 or 1.
3. The C-3 substituted oleanolic acid benzylamide derivative according to claim 2, It is characterized in that The R 1 Each independently selected from hydrogen, hydroxyl, C 1~3 Alkoxy or halogen.
4. The C-3 substituted oleanolic acid benzylamide derivative according to claim 3, It is characterized in that The R 1 Each independently selected from hydrogen, hydroxyl, C 1~3 Alkoxy or fluorine.
5. The C-3 substituted oleanolic acid benzylamide derivative according to claim 4, It is characterized in that The R is selected from phenol, diphenol, pyrogallol, C 1~3 Alkoxy substituted phenyl, difluorophenyl, dihydroxy substituted benzyl or trihydroxy substituted cyclohexenyl.
6. The C-3 substituted oleanolic acid benzylamide derivative according to claim 5, It is characterized in that The R is selected from 4-hydroxy substituted phenyl, 3,4-dihydroxy substituted phenyl, 3,4,5-trihydroxy substituted phenyl, 2,3-dihydroxy substituted phenyl, 3,5-dihydroxy substituted phenyl, 2,4-dihydroxy substituted phenyl, 3,4-dimethoxy substituted phenyl, 3,4-difluoro substituted phenyl, 3,4-dihydroxy substituted benzyl or 3,4,5-trihydroxy substituted cyclohexenyl.
7. The C-3 substituted oleanolic acid benzylamide derivative according to any one of claims 1 to 6, It is characterized in that The C-3 substituted oleanolic acid benzylamide derivative also includes pharmaceutically acceptable salts, crystal forms, solvates, stereoisomers or isotope-substituted compounds thereof.
8. A method for preparing a C-3 substituted oleanolic acid benzylamide derivative according to any one of claims 1 to 6, It is characterized in that The steps include: S1. Oleanolic acid was used as the raw material and acetylated at room temperature to obtain the intermediate compound 1: S2. At room temperature, the intermediate compound 1 obtained in step S1 is reacted with oxalyl chloride to generate an acyl chloride intermediate, triethylamine is added as an acid binding agent, and then condensed with benzylamine to generate an intermediate compound 2: S3. At 45-50° C., the intermediate compound 2 obtained in step S2 is hydrolyzed under the action of an alkaline reagent to obtain an intermediate compound 3: S4. Under ice bath conditions, the intermediate compound 3 obtained in step S3 and compound P-1 are mixed evenly, and a condensation reaction is carried out under an inert protective atmosphere at room temperature to obtain an intermediate compound 4: S5. Under normal temperature conditions, the intermediate compound 4 obtained in step S4 is selectively removed from the TBDMS protecting group to obtain the intermediate compound 5: S6. Under ice bath conditions, the intermediate compound 5 obtained in step S5 and compound P-2 are uniformly mixed, and a condensation reaction is carried out under an inert protective atmosphere at room temperature to obtain an intermediate compound 6-n: S7. Under normal temperature and inert protective atmosphere, the intermediate compound 6-n obtained in step S6 is selectively deprotected by Boc protecting group to obtain an intermediate compound of the general formula 7-n: S8. Under ice bath conditions, the intermediate compound obtained in step S7 is mixed evenly with compound P-3, and a condensation reaction is carried out under an inert protective atmosphere and room temperature conditions to obtain an intermediate compound of the general formula 8-n: Wherein, the definition of R' is: when R in Formula I is R 1 (m1) Substituted benzene ring or R 2 (m2) substituted benzyl, and R 1 , R 2 is a hydroxyl group, then R' is the group after the hydrogen of the hydroxyl group in R is replaced by Bn; when the R is selected from R 3 (m3) Replace C 3~6 Cycloalkenyl, and R 3 is a hydroxyl group, then R' is the group after the hydrogen of the hydroxyl group in R is replaced by TBDMS: In other cases, R' has the same definition as R; S9. When R 'does not contain TBDMS: Under normal temperature conditions and a hydrogen atmosphere, the intermediate compound 8-n obtained in step S8 is deprotected from the benzyl protecting group to obtain the C-3 substituted oleanolic acid benzylamide derivative; When R' contains TBDMS: at room temperature, the intermediate compound 8-n obtained in step S8 is first selectively deprotected from the TBDMS protecting group, and then the benzyl protecting group is deprotected at -75 to -80°C in an inert protective atmosphere to obtain the substituted oleanolic acid benzylamide derivative with C-3: Wherein, the definitions of n and R are the same as those in any one of claims 1 to 6.
9. Use of the C-3 substituted oleanolic acid benzylamide derivative according to any one of claims 1 to 7 in the preparation of anti-influenza virus drugs.
10. An anti-influenza virus drug, It is characterized in that Contains one or more of the C-3 substituted oleanolic acid benzylamide derivatives according to any one of claims 1 to 7.
Citation Information
Patent Citations
Preparation method and application of antitumor drug X-TOA
CN105622704A
Triterpene Derivative and Its Anti-Influenza Use
US20150274766A1
Triterpene derivatives and medicinal composition
WO1998058946A1
Cited By
C-3-substituted pentacyclic triterpene benzamide derivative as well as preparation method and application thereof
CN120025395A
